Medication, Vaccine, and Folic Acid Use Among Pregnant Women in Belgium: Insights from the <scp>BELpREG</scp> Cohort
BACKGROUND: Safety data for most medications in pregnancy remain limited, yet pharmacological treatment is often necessary. Evidence on real-world medication use in pregnancy including over-the-counter products and folic acid is scarce, especially in Belgium. METHODS: We conducted a drug utilization study using self-reported data from BELpREG, a prospective, web-based pregnancy registry established in November 2022. Pregnant individuals aged ≥ 18 years receiving healthcare in Belgium can enrol voluntarily at any stage in pregnancy and complete online questionnaires at enrolment and every four weeks until delivery. All participants with follow-up beyond the first trimester were included, and trimester-specific cohorts were constructed based on completion of questionnaires after each trimester. Data were extracted in July 2025. RESULTS: This study included 2096 participants, of whom 1767 were followed through trimester 2 and 1136 through trimester 3. Median gestational age at enrolment was 16 weeks. Prevalence estimates of medication use were 80.2% in the six months before conception, 85.8% in trimester 1, 92.0% in trimester 2, and 94.9% in trimester 3. The most common classes were analgesics, vaccines, antihistamines, antianemic preparations, and drugs for acid-related disorders. Paracetamol was most frequently used (35.4% in trimester 1), typically short term (median 3 days), followed by doxylamine-pyridoxine (26.7% in trimester 1). Folic acid supplementation was nearly universal, though only 59.9% met national guideline-concordant criteria. Maternal vaccine uptake was substantial but incomplete, with 66.5% receiving pertussis, 43.7% influenza, and 24.4% COVID-19 vaccination. Exposure to potentially inappropriate or teratogenic medications was rare. CONCLUSIONS: Medication use during pregnancy in Belgium was nearly universal, with high use of paracetamol and doxylamine-pyridoxine. Folic acid and vaccine uptake were substantial, but often not guideline-concordant.
Authors
- Anne Smits
- Michael Ceulemans (ORCID: https://orcid.org/0000-0002-4130-5869)
- Titia Hompes (ORCID: https://orcid.org/0000-0002-6206-0389)
- Jan Y. Verbakel (ORCID: https://orcid.org/0000-0002-7166-7211)
- Maarten De Vos (ORCID: https://orcid.org/0000-0002-3482-5145)
- Laure Sillis (ORCID: https://orcid.org/0000-0002-7545-2357)
- Veerle Foulon (ORCID: https://orcid.org/0000-0002-4053-3915)
- Sien Lenie (ORCID: https://orcid.org/0009-0000-8786-4765)
- Kristel Van Calsteren
- Emily Jacobs
- Karel Allegaert (ORCID: https://orcid.org/0000-0001-9921-5105)
Institutions
- Research Foundation - Flanders (BE)
- University of Oxford (GB)
- University of Plymouth (GB)
- Erasmus University Rotterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1002/pds.70369
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00